In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA.

Given concerns about the need for toilet access while out in the community, particularly for individuals with health conditions and disabilities, we have compiled a list of public toilets in the ...

Mirikizumab shows early and sustained efficacy in reducing bowel urgency and achieving remission in patients with moderate-to ...

We often ignore stomach pain by saying that it might be due to gas or that we might have eaten too much. However, it is a ...

Hello, readers! Welcome to a bonus letters column. We are happy to report that you are keeping our inboxes busy, so we’ll dive right in.